Talk:Janssen Vaccines

products
someone should ad Aerugen to the products, a vaccine against pseudomonas aeruginosa with cystic fibrosis. —Preceding unsigned comment added by 138.232.38.35 (talk) 12:54, 28 July 2009 (UTC)

External links modified
Hello fellow Wikipedians,

I have just modified 2 external links on Crucell. Please take a moment to review my edit. If you have any questions, or need the bot to ignore the links, or the page altogether, please visit this simple FaQ for additional information. I made the following changes:
 * Added archive https://web.archive.org/web/20110708205305/http://crucell.com/annual_report_2009/pdfs/Crucell_AR09_Complete.pdf to http://crucell.com/annual_report_2009/pdfs/Crucell_AR09_Complete.pdf
 * Added archive https://web.archive.org/web/20141030063618/http://www.crucell.com/TECHNOLOGY.HTM to http://www.crucell.com/TECHNOLOGY.HTM

When you have finished reviewing my changes, you may follow the instructions on the template below to fix any issues with the URLs.

Cheers.— InternetArchiveBot  (Report bug) 00:10, 15 August 2017 (UTC)

unsourced
moved here from History section, per WP:PRESERVE

In 1993 Introgene, Crucell’s predecessor, was established as a spin-off of Leiden University. The company formed a partnership with Genzyme to collaborate on its vector technology and viral-based products. In 1999 the company founded Galapagos Genomics as a joint venture together with Tibotec. In 2000 IntroGene acquired U-Bisys to form Crucell.

In 2006, Crucell and Swiss Berna Biotech, Swedish SBL Vaccines and US-based Berna Products joined forces to become the sixth largest vaccine company worldwide, with their own clinical programs.

On 7 January 2009 Crucell released a press release saying Crucell and Wyeth were in discussion on a merger of the two companies. On 26 January 2009 Crucell released another press release saying the discussions on a combination of Crucell and Wyeth was discontinued due to Pfizer's acquisition of Wyeth.

-- Jytdog (talk) 19:57, 2 February 2018 (UTC)